Ryvu Therapeutics SA
No trades
−5.15 PLN
−111.44 M PLN
77.97 M PLN
19.02 M
About Ryvu Therapeutics SA
Sector
Industry
CEO
Pawel Przewiezlikowski
Website
Headquarters
Kraków
Founded
2007
Identifiers
2
ISINPLSELVT00013
Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. Its projects and services include contract chemistry services, biology services, integrated drug discovery, and comparative studies of biosimilar medicinal products. The company was founded by Boguslaw Sieczkowski and Pawel Przewiezlikowski in 2007 and is headquartered in Krakow, Poland.
Related stocks
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
ETFBS80TR
Beta ETF sWIG80TR Portfelowy Fundusz Inwestycyjny Zamkniety UnitsWeight
1.47%
Market value
671.28 K
USD
Explore more ETFs
Frequently Asked Questions
The current price of RVU is 25.35 PLN — it has decreased by −1.74% in the past 24 hours. Watch Ryvu Therapeutics SA stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GPW exchange Ryvu Therapeutics SA stocks are traded under the ticker RVU.
RVU stock has fallen by −0.98% compared to the previous week, the month change is a 6.51% rise, over the last year Ryvu Therapeutics SA has showed a −34.16% decrease.
We've gathered analysts' opinions on Ryvu Therapeutics SA future price: according to them, RVU price has a max estimate of 48.00 PLN and a min estimate of 27.80 PLN. Watch RVU chart and read a more detailed Ryvu Therapeutics SA stock forecast: see what analysts think of Ryvu Therapeutics SA and suggest that you do with its stocks.
RVU stock is 2.99% volatile and has beta coefficient of 1.18. Track Ryvu Therapeutics SA stock price on the chart and check out the list of the most volatile stocks — is Ryvu Therapeutics SA there?
Today Ryvu Therapeutics SA has the market capitalization of 586.08 M, it has decreased by −1.92% over the last week.
Yes, you can track Ryvu Therapeutics SA financials in yearly and quarterly reports right on TradingView.
RVU net income for the last quarter is −24.71 M PLN, while the quarter before that showed −33.66 M PLN of net income which accounts for 26.59% change. Track more Ryvu Therapeutics SA financial stats to get the full picture.
No, RVU doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 24, 2025, the company has 328 employees. See our rating of the largest employees — is Ryvu Therapeutics SA on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ryvu Therapeutics SA EBITDA is −131.81 M PLN, and current EBITDA margin is −173.50%. See more stats in Ryvu Therapeutics SA financial statements.
Like other stocks, RVU shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ryvu Therapeutics SA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ryvu Therapeutics SA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ryvu Therapeutics SA stock shows the sell signal. See more of Ryvu Therapeutics SA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.